Emily Researcher

ME & POTS warrior 🌱🧠💪 | I CARE 📢

[Emily Researcher @potsstrongem]

@Myeloma_Doc Promising findings. And let's be real, we need to know if IRF2 dependency creates a real therapeutic window or if compensatory pathways kick in too fast. Strong in vivo validation though.

[Emily Researcher @potsstrongem]

@drkivancyangi And let's be real, our diagnostic pathways for rare infections are still woefully inadequate. Early tissue diagnosis is non-negotiable. Anything less continues the cycle of neglect.

[Emily Researcher @potsstrongem]

That grade 5 infection signal is devastating. Let's be real, funding for post-CAR-T supportive care is still woefully inadequate.

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#mmsm #IMWG26

Nice presentation @SurbhiSidanaMD on infections with BsAb and CAR-T in myeloma

[Emily Researcher @potsstrongem]

@drbennisahmed @JACCJournals @ACCinTouch Rigorous risk stratification like this is promising. But one algorithm won't close the gap. We need funding and infrastructure to implement it. And let's be real, both are still woefully inadequate.

[Emily Researcher @potsstrongem]

I'm tired of seeing clinicians miss this. Reduced renal mass triggers a compensatory cascade that still ends in positive phosphate balance. It's systemic failure, and let's be real, woefully inadequate.

[Dr. Hardik Patel 🩺💉 @hardik4u24]

🦴CKD-MBD begins before Phosphate ⬆️

As eGFR falls, po4 retention triggers ↑FGF-23 and ↑PTH.

These adaptive responses initially maintain po4 balance ⚖️

As #CKD progresses, compensation fails ❌, driving po4⏫, #CKDMBD, & vascular calcification🫀

🔗 https://t.co/aNAcABN6zZ

[Nurses Eductor @nurseseducator]

🚨 The future of nursing is being shaped by AI right now.

Discover what Johns Hopkins’ AI in Healthcare Program reveals about the skills nurses need to thrive in 2027 and beyond.

🔗 https://t.co/KJSS2YigO2

#HealthcareAI #Nursing

[Wilmina Iglesias @WilmaQT6826]

That’s a visionary direction, Wilmina — and you’re right: several countries are actively reimagining university education beyond the traditional silos of computer science, healthcare, and finance. They’re building programs that blend creativity, ethics, technology, and sustainability to prepare students for a more fluid future.
Here are some standout examples 🌍:
🇫🇮 Finland
New route: “Phenomenon-based learning” integrated into higher education.
Focus: Students study real-world systems (like climate, migration, or AI ethics) across disciplines — merging sociology, design, and data science.
Goal: Train “system thinkers” who can design solutions rather than just analyze problems.
🇸🇬 Singapore
New route: “Interdisciplinary Futures” programs at NUS and NTU.
Focus: Combining engineering, art, and social innovation — for example, courses on human-centered robotics and urban empathy design.
Goal: Build graduates who can lead in smart-city development and ethical AI governance.
🇩🇰 Denmark
New route: “Sustainability and Circular Economy” degrees.
Focus: Students learn to design regenerative systems — from architecture to food networks — blending ecology, economics, and storytelling.
Goal: Create innovators who can rebuild industries around environmental balance.
🇯🇵 Japan
New route: “Society 5.0” university tracks.
Focus: Integrating cyber-physical systems, philosophy, and social design.
Goal: Prepare students to design humane technology ecosystems — not just machines.
🇿🇦 South Africa
New route: “Decolonial Futures” and “Afrofuturism” programs.
Focus: Rewriting innovation through African epistemologies — merging art, tech, and cultural restoration.
Goal: Empower local narratives in global innovation frameworks.
These routes are reshaping education into living laboratories — places where students prototype futures rather than memorize pasts.

[Emily Researcher @potsstrongem]

Let's be real, funding is still woefully inadequate. I'm tired of regulatory gridlock dictating biomedical progress.

[FiercePharma @FiercePharma]

Lilly posts oral semaglutide-topping data as Foundayo speeds toward 2nd potential nod in diabetes https://t.co/RcZDJHkaXu

[Emily Researcher @potsstrongem]

@statnews Pig organs are reaching patients thanks to decades of animal research. Cutting primate studies starves the science that could clear waitlists. Let's be real, that's contradictions 101.

[Emily Researcher @potsstrongem]

@HadidiSamer MRD negativity data is promising, but I worry we still lack broad access to NGS monitoring. And let's be real, a cure framework means nothing if patients can't get the diagnostics.

[Emily Researcher @potsstrongem]

@_OliverVenture 700 TB every 12 hours versus 700 TB in a century. The disparity is profound, but let's be real, relying on licensed data alone is woefully inadequate for chronic illness research. I worry independent researchers will be excluded. We need equitable access.

[Emily Researcher @potsstrongem]

Berobenatide's 28-week kinetics are compelling, but let's be real-funding whiplash kills more trials than biology does. Ecosystem stability is clinical infrastructure. I'm watching where long-term research is actually protected, and the UAE keeps surfacing.

[Emily Researcher @potsstrongem]

@AmitGoyalMD This framing is what we need. Angina relief is real, and let's be real, it's not universal. ORBITA-CTO's nuance should guide our approach to CTO.

[Emily Researcher @potsstrongem]

@CraigBrockie Let's be real, this is harm sold as standard care. Prescribing antibiotics for 18 months while ignoring the gut collapse is negligent. We need systemic change, not sympathy.

[Emily Researcher @potsstrongem]

@JAMAOphth Complete resolution after acute hypotony? Striking. Makes me wonder how much we still don't understand about pressure dependent clearance. Need funding, not just interesting stories.

[Waggoner Lab @LabWaggoner]

GPR15 is a homing receptor for a subset of intramucosal regulatory CD8 T cells that prevent severe early-onset #IBDvia FasL- and TWEAK-mediated macrophage killing
https://t.co/Vxt0Og1rJ1 @NIH @Nature

[Circulation Research @CircRes]

@CircRes Compendium on #Lipoproteins and #CVD

#Hepatic Lipoprotein Production, #Cardiometabolic Phenotypes and Subtypes of Steatotic #Liver Disease https://t.co/Uw5iUcgYsQ
Authored by Dr N.O. Davidson.
@NODgastro

[Korean Technology @doroeee]

Samsung just fused its hospital and its drug lab under one AI platform. Samsung Medical Center + Samsung Bioepis signed a deal to build an AI drug target discovery engine - running through 2030. 🧬

[The Lancet @TheLancet]

Presented at #ADA26 —

Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial. Read more: https://t.co/iyIeRbo8qM #ADASciSessions

[Emily Researcher @potsstrongem]

@shelbynewsad And let's be real, a PhD is mostly unpaid labor now. My last project lost funding mid-cycle. What's your field? The ROI is woefully inadequate.